The funding from crowdfunding platform SyndicateRoom is part of a wider series B round for Manchester gel therapy developer Gelmetix and adds to approximately $1.3m raised in 2014 and 2015.

Strategic partner Eli Lilly invested $15m while Pfizer, Ping An Ventures and Taiho Ventures also contributed to the immunotherapy developer's series B round.

Pfizer Ventures and 6 Dimensions Capital joined Merck & Co, Sanofi, Eli Lilly and Amgen in Kymera's series B round, taking the protein degradation drug developer's total funding to more than $95m.

Kaiser Permanente-backed respiratory device provider Vapotherm floated at the bottom of its range but raised $56m in its initial public offering.

The Medtronic and BioMed Realty-backed medical device developer bumped its overall funding to $113m with a round led by Solas BioVentures.

The sleep disorder treatment developer has raised an additional $17.1m in a round led by medical device maker Cochlear.

Boehringer Ingelheim and Helsinn helped University of Geneva vaccine spinout Amal reach the second close of a series B round that now totals $32.7m.

Existing investors SoftBank Vision Fund and Dexxon both returned for a $200m round that will help drug developer Roivant Sciences expand its range of subsidiaries.

Merck & Co, AstraZeneca and Alexion are all in line for exits after Moderna Therapeutics, valued at $7.5bn earlier this year, filed for its initial public offering.

GetWellNetwork has bolstered its digital experience by acquiring the patient engagement platform, giving exits to iCarbonX, Lafayette General and Summation Health Ventures.